FLT3 and acute myeloid leukemia: Cesar Sommer et al. generated a kind of scFv-containing FLT3-CAR-T and examined its effects in a preclinical setting [109], and discovered that they removed primary AML primitive cells, as well as hematopoietic stem and progenitor cells, which bring certain bone marrow toxicity.